Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium – QNT Press Release


SEATTLE, Sept. 14, 2022 /PRNewswire/ — Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium. The virtual event will take place on September 232022.

“I am excited to join leading immuno-oncology experts in discussing the latest advances in anti-VISTA immunotherapies,” said Dr. Guillaudeux. “VISTA is an important myeloid checkpoint with a unique mechanism of action bridging innate and adaptive immunity. Anti-VISTA therapies have great potential to improve cancer treatment outcomes in a variety of solid tumors, especially for patients resistant to standard of care therapies including first generation immune checkpoint inhibitors.”

Dr. Guillaudeux will join leading researchers and clinicians in immunology to discuss new insights into VISTA, a promising therapeutic target for cancer. The symposium will focus on VISTA’s function and applicability in cancer immunology, as well as the latest research and development in programs targeting VISTA .

Presentation Details:
Session Title: VISTA Biology
Date: September 23, 2022
Time: 9:20 AM to 10:00 AM Eastern Time

Session Title: Anti-VISTA Therapeutic Strategies
Date: September 23, 2022
Time: 12:10 PM to 12:55 PM Eastern Time

Click on the link below for additional details and to register for the symposium:
https://www.eventbrite.com/e/2nd-annual-vista-symposium-tickets-374510088757

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center